Introduction {#Sec1}
============

Pilocytic astrocytomas (WHO grade I) are the most common central nervous system tumors in the 5 to 19 year age group. They are cystic, well-circumscribed tumors, which rarely progress and can usually be removed using surgery \[[@CR9]\]. This accounts for their having a more favourable prognosis than diffuse and other infiltrative astrocytomas \[[@CR39]\]. Molecular studies on pilocytic astrocytomas have identified recurrent *BRAF* gene fusions and other alterations that activate the ERK/MAPK signal transduction pathway \[[@CR15], [@CR27], [@CR56]\]. Activated ERK/MAPK signaling is believed to drive cellular proliferation and then to trigger senescence, giving rise to the indolent phenotype of pilocytic astrocytomas \[[@CR24], [@CR42]\].

MicroRNAs are short RNA molecules that modulate gene expression post-transcriptionally by repressing translation or degrading the mRNA transcript \[[@CR26]\]. They regulate numerous biological processes including cell proliferation and differentiation, and have major roles in embryogenesis, including brain and spinal cord development and neurogenesis \[[@CR13], [@CR41]\]. Many microRNAs are involved in the initiation and progression of cancer \[[@CR3], [@CR37]\], and recent studies of pediatric brain tumors have identified tumor-specific microRNA signatures \[[@CR5], [@CR21], [@CR38]\].

To further our knowledge of the molecular drivers of pilocytic astrocytomas, we conducted a detailed investigation of microRNA and gene expression in these tumors, and characterised the findings by pathway analysis. Our results revealed a distinctive microRNA and gene expression profile in pilocytic astrocytoma compared to other pediatric brain tumors. We found that many predicted targets of up-regulated microRNAs in pilocytic astrocytomas are known regulators of the ERK/MAPK and NF-κB pathways. These findings suggest an important modulatory role for microRNAs in critical pathways involved in pilocytic astrocytomas.

Materials and methods {#Sec2}
=====================

Tumor samples and controls {#Sec3}
--------------------------

miRNA and mRNA profiling was performed on a range of fresh frozen brain tumor samples (the *test* cohort) from 57 children, aged 1--16 years, and on 7 normal adult brain controls (4 frontal lobe and 3 cerebellum, Biochain) (Table [1a](#Tab1){ref-type="table"}). A further 13 pediatric brain tumor samples were used as a *validation* cohort (Table [1b](#Tab1){ref-type="table"}). Tumors were classified using criteria defined by the World Health Organization (WHO) \[[@CR36]\]. Access to samples and clinical data complied with Local Research Ethics Committee (LREC) regulations: Great Ormond Street Hospital LREC reference number 05/Q0508/153. All the *test* pilocytic astrocytomas were shown previously to contain the *KIAA1549-BRAF* gene fusion \[[@CR32]\]. The *BRAF* V600E mutation was also examined in the high-grade astrocytomas in the *test* cohort. *KIAA1549-BRAF* fusion and the *BRAF* V600E mutations were also tested in the *validation* cohort using PCR according to published protocols \[[@CR32], [@CR45]\].Table 1Pediatric tumor cohortsTumorPathologyGradeLocationSexAgeBRAF statusa.PGNTPapillary glioneuronalIFrontal lobeM14ndPA1Pilocytic astrocytomaIPosterior fossaF16*KIAA1549-BRAF* exon 16-exon 9PA2Pilocytic astrocytomaIPosterior fossaM12*KIAA1549-BRAF* exon 16-exon 9PA3Pilocytic astrocytomaIPosterior fossaM14*KIAA1549-BRAF* exon 16-exon 9PA5Pilocytic astrocytomaIPosterior fossaF3*KIAA1549-BRAF* exon 16-exon 9PA6Pilocytic astrocytomaICerebellumF8*KIAA1549-BRAF* exon 15-exon 9PA7Pilocytic astrocytomaICerebellumM1*KIAA1549-BRAF* exon 16-exon 11PA8Pilocytic astrocytomaICerebellumM1*KIAA1549-BRAF* exon 16-exon 9PA9Pilocytic astrocytomaICerebellumF2*KIAA1549-BRAF* exon 16-exon 11PA10Pilocytic astrocytomaICerebellumM2*KIAA1549-BRAF* exon 16-exon 9PA11Pilocytic astrocytomaICerebellumM6*KIAA1549-BRAF* exon 16-exon 9PA12Pilocytic astrocytomaICerebellumF11*KIAA1549-BRAF* exon 15-exon 9PA13Pilocytic astrocytomaIPosterior fossaM4*KIAA1549-BRAF* exon 16-exon 9PA14Pilocytic astrocytomaIPosterior fossaF6*KIAA1549-BRAF* exon 16-exon 9PA15Pilocytic astrocytomaIPosterior fossaM9*KIAA1549-BRAF* exon 16-exon 9DA1Diffuse astrocytomaIITemporal lobeF12No *BRAFV600E*DA2Diffuse astrocytomaIIUnknownF14No *BRAFV600E*DA3Diffuse astrocytomaIIOccipital lobeM4ndDA4 \*Diffuse astrocytomaIIUnknownM17*BRAFV600E* presentAA1Anaplastic astrocytomaIIIConus medullarisM15ndAA2Anaplastic astrocytomaIIITemporal lobeF3No *BRAFV600E*AA3 \*Anaplastic astrocytomaIIIUnknownF11No *BRAFV600E*GBM1GlioblastomaIVFrontal lobeF15No *BRAFV600E*GBM2GlioblastomaIVTemporoparietalM10No *BRAFV600E*GBM3GlioblastomaIVBrainstemF4ndGBM4GlioblastomaIVLeft frontal lobeF10No *BRAFV600E*GBM5GlioblastomaIVSpinal cordF7ndE1EpendymomaIIIPosterior fossaM4E2EpendymomaIIIParietal lobeF6E3EpendymomaIIPosterior fossaF2E4EpendymomaIIIPosterior fossaF2E5EpendymomaIITemporal lobeM12E6EpendymomaIIIPosterior fossaM6E7EpendymomaIIIPosterior fossaM2E8EpendymomaIISupratentorial (frontal)M14E9EpendymomaIIPosterior fossaM3E10EpendymomaIIPosterior fossaM4E11EpendymomaIIIPosterior fossaFndE12EpendymomaIIIFourth ventricleM1E13EpendymomaIISpinal seedF6E14EpendymomaIIIPosterior fossaF6M1MedulloblastomaIVPosterior fossaM4M2MedulloblastomaIVPosterior fossaM1M3MedulloblastomaIVPosterior fossaF6 monthsM4MedulloblastomaIVPosterior fossaM7M5MedulloblastomaIVPosterior fossaM3M6MedulloblastomaIVPosterior fossaM9M7MedulloblastomaIVPosterior fossaM7M8MedulloblastomaIVPosterior fossaM9M9MedulloblastomaIVPosterior fossaM4M10 \*MedulloblastomaIVPosterior fossaF5R1Atypical RhabdoidIVBrainstemM1R2Atypical RhabdoidIVPosterior fossaF7 monthsR3Atypical RhabdoidIVSupratentorialF2R4Atypical RhabdoidIVPosterior fossaM9 monthsR5Atypical RhabdoidIVPosterior fossaF2 monthsP1Choroid Plexus PapillomaIIntraventricular (frontal lateral ventricle)M10 monthsP2Choroid Plexus PapillomaIPosterior fossaM1P3Choroid Plexus PapillomaILeft lateral ventricleM3P4Choroid Plexus PapillomaIUnknownFndAC1Adult control cerebellumCerebellumM22AC2Adult control frontal lobeFrontal lobeM41AC3Adult control cerebellumCerebellumM21AC4Adult control cerebellumCerebellumM26AC5Adult control frontal lobeFrontal lobeM82AC6Adult control frontal lobeFrontal lobeM25AC7Adult control frontal lobeFrontal lobeM27b.PA16Pilocytic astrocytomaIPosterior fossaM9ndPA17Pilocytic astrocytomaIPosterior fossaM12ndPA18Pilocytic astrocytomaISuprasellarM3*KIAA1549-BRAF* exon 15-exon 9PA19Pilocytic astrocytomaI3^rd^ ventricleM16ndPA20Pilocytic astrocytomaIBrain stemF3*KIAA1549-BRAF* exon 15-exon 9PA21Pilocytic astrocytomaIPosterior fossaF4*KIAA1549-BRAF* exon 16-exon 9PA22Pilocytic astrocytomaIPosterior fossaM16*KIAA1549-BRAF* exon 16-exon 9PA23Pilocytic astrocytomaIPosterior fossaF2*KIAA1549-BRAF* exon 16-exon 11PA24Pilocytic astrocytomaIPosterior fossaF12*KIAA1549-BRAF* exon 16-exon 9GBM6GlioblastomaIVMidbrain/ThalamusF14-GBM7GlioblastomaIVOccipital lobeM4 months-GBM8GlioblastomaIVThalamic/intraventriclarF10-GBM9GlioblastomaIIThalamicM15-(a) Test cohort analysed using Illumina MicroRNA Expression Arrays (MI-v2) and Illumina HumanHT-12_v3 Beadchip system, with the exception of samples marked with an asterisk (\*), that were used for validation only(b) Validation cohort used for confirmation of differentially expressed microRNAs and genes. Annotation: − negative, *nd* not determined

MicroRNA and gene expression arrays {#Sec4}
-----------------------------------

MicroRNA expression was profiled in the *test* tumor cohort and the normal brain controls using Illumina MicroRNA Expression Arrays (MI-v2). This system screens 1,146 known and putative microRNAs including 97 % of microRNAs in miRBase (Release 12.0). Gene expression profiles were obtained for the same tumors and controls using the Illumina HumanHT-12_v3 Beadchip system. RNA was extracted from the samples using TRIzol (Invitrogen) and eluted into RNAse-free water using the RNeasy mini kit (Qiagen). cDNA was synthesized using random hexamers and the SuperScript First-Strand cDNA synthesis system (Invitrogen). Hybridization and scanning were performed in-house at the Barts and The London Genome Centre.

Statistical analysis {#Sec5}
--------------------

The microRNA and gene expression-averaged tumor profiles were compared to normal adult brain controls using GenomeStudio and GeneSpring Multi-Omic Analysis v12.1 software. Data were subjected to thresholding, log transformation (log2), normalization (quantile) and baseline transformation (median to all samples). Normalized data of microRNA and gene expression are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1 and Additional file [2](#MOESM2){ref-type="media"}: Table S2. All data were deposited in NCBI's Gene Expression Omnibus \[[@CR12]\] (<http://www.ncbi.nlm.nih.gov/geo>) and are accessible through GEO accession number GSE42658. Differential expression was defined as fold change (FC) \> 2 with FDR corrected (Benjamini Hochberg) *p-*values \< 0.05. Unsupervised hierarchical clustering (Euclidean method), was performed on both the microRNA and mRNA expression data. The differentially expressed microRNAs and genes are listed in Additional file [3](#MOESM3){ref-type="media"}: Table S3 and Additional file [4](#MOESM4){ref-type="media"}: Table S4 for tumor groups with more than three samples.

Pathway analysis {#Sec6}
----------------

Ingenuity Pathway Analysis (Ingenuity Systems Inc., Redwood City, USA) was used to identify over-represented pathways for significantly differentially expressed genes in pilocytic astrocytomas. The significance value associated with the functional analysis is expressed as a *p-*value calculated by comparing the number of differentially expressed genes that participate in a given function or pathway, relative to the total number of occurrences of these proteins in all functional/pathway annotations stored in Ingenuity Pathway Knowledge Base. Multiple-testing corrected *p-*values were calculated using the Benjamini-Hochberg method. For each functional annotation, a statistical quantity is calculated called the regulation z-score. The purpose of the z-score is to identify increased or decreased biological functions that are likely implicated by the observed gene expression changes. Hence, the *p-*values measure the observed and predicted regulated gene sets, and the z-score assesses the match of the observed and predicted up/down regulation patterns. For this study, we only considered a predicted activation/inhibition status as significant if the *p-*value was \< +/−0.05 and the z-score \> 2.0 or \< 2.0 respectively.

Taqman microRNA assays {#Sec7}
----------------------

TaqMan miRNA assays were used to validate differentially expressed microRNAs of interest. Control microRNAs RNU48 and miR-423-3p were tested for stability over all tumors and miR-423-3p was selected as the most stable control. Hence all samples were normalized to miR-423-3p and fold change calculated relative to the average expression in adult cerebellum and frontal lobe (BioChain, A508112 and B210079 respectively). Differential expression was validated for miR-542-3p, miR-503, miR-146a, miR-34a, miR-155, miR-124\*, miR-129 and miR-129\*. TargetScan Release 6.2 (<http://www.targetscan.org>) was used to search for predicted targets of microRNAs of interest. MicroRNAs are named using the "miR' prefix and a unique identifying number which is assigned sequentially \[[@CR2]\]. Identical or very similar miRNA sequences within a species can be given the same number, with their genes distinguished by a letter and/or numerical suffixes (e.g. miR-450a and miR-450b are slightly different in sequence, whereas those of miR-450a-1 and miR-450a-2 are identical). Some miRNA hairpin precursors give rise to two excised miRNAs, one from each arm. Previous annotations used the nomenclature miR-124 and miR-124\* for the guide and passenger strand respectively, and some of these names were included in our Illumina MicroRNA Expression Arrays (MI-v2). However, the mature sequences derived from both arms of the hairpin may be biologically functional, so current nomenclature uses miR-542-5p and miR-542-3p to designate miRNAs from the '5' and '3' arms respectively, \[[@CR18], [@CR29]\].

RT-qPCR {#Sec8}
-------

PCR primers were designed using Primer 3 software (<http://frodo.wi.mit.edu/primer3/>) (Additional file [5](#MOESM5){ref-type="media"}: Table S5). RT-qPCR was used to quantify the levels of mRNA expression for selected genes, using SYBR Green JumpStart Taq ReadyMix kit (Sigma-Aldrich), 50 ng cDNA, and 0.1 μM primers in a reaction volume of 20 μl. Assays were run on an ABI 7500 Real Time PCR System (ABI). PCR analyses were conducted in triplicate for each sample and melting curves analyzed for correct product size. Control genes *TBP* and *CREB1* were tested for stability over all tumors, and *TBP* selected as the most stable endogenous control. Therefore, all samples were normalized to *TBP* and fold change calculated relative to the average expression in adult cerebellum (BioChain, A508112), and frontal lobe (BioChain B210079). Relative quantification was calculated using the 2-ddC~t~ method \[[@CR35]\].

Results {#Sec9}
=======

Characterization of the pediatric brain tumor cohort {#Sec10}
----------------------------------------------------

We first examined microRNA and gene expression in the *test* tumor cohort that consisted of a papillary glioneuronal tumor (*n* = 1), pilocytic astrocytomas (*n* = 14), diffuse astrocytomas (*n* = 3), anaplastic astrocytomas (*n* = 2), glioblastomas (*n* = 5), atypical teratoid rhabdoid tumors (AT/RT) (*n* = 5), medulloblastomas (*n* = 9), ependymomas (*n* = 14) and choroid plexus papillomas (*n* = 4), total = 57 samples (Table [1a](#Tab1){ref-type="table"}). Differential microRNA expression across the averaged tumor groups was calculated to obtain fold changes compared to normal adult brain controls (FDR \< 0.05, Additional file [3](#MOESM3){ref-type="media"}: Table S3). The number of up- and down-regulated microRNAs for each tumor type is shown in Table [2](#Tab2){ref-type="table"}. Unsupervised hierarchical clustering (Euclidean method) of microRNAs clustered the tumors by pathology in the low-grade tumors, and showed higher-grade tumors to be more widely distributed (Fig. [1a](#Fig1){ref-type="fig"}). A similar pattern was also found using gene expression data (Additional file [2](#MOESM2){ref-type="media"}: Table S2), with higher-grade tumors showing greater heterogeneity than low-grade tumors (Fig. [1b](#Fig1){ref-type="fig"}). Following initial comparison with other tumor types, microRNA profiles were then investigated in detail in pilocytic astrocytomas, all of which contained the *KIAA1549:BRAF* gene fusion.Table 2Number of differentially expressed microRNAs in pediatric brain tumors compared to normal adult brainPathology*n*RegulationTotalUpDownPilocytic astrocytoma14424991Pilocytic astrocytoma^a^14273360Diffuse astrocytoma3123Anaplastic astrocytoma26814Glioblastoma5055Ependymoma146075135Medulloblastoma9253560Medulloblastoma^a^9102939Atypical Teratoid/Rhabdoid tumor5151732Choroid plexus papilloma44763110^a^Pilocytic astrocytomas and medullobastomas were also compared to normal adult cerebellum. Fold change \> 2 with a FDR corrected *p*-value \< 0.05Fig. 1Hierarchical clustering of microRNA and mRNA expression stratifies tumor subgroups. Unsupervised hierarchal clustering (Euclidean method) was performed on (**a**) microRNA and (**b**) mRNA expression data. Tumors represented as: PA-pilocytic astrocytoma, PGNT-papillary glioneuronal tumor, DA-diffuse astrocytoma, AA-anaplastic astrocytoma, GBM-glioblastoma, E-ependymoma, M-medulloblastoma, R-atypical rhabdoid tumor, P-choroid plexus papilloma and AC1, AC3, AC4-adult control cerebellum and AC2, AC5, AC6, AC7-adult control frontal lobe. nd -- not determined

MicroRNA profile and the predicted targeted pathways in Pilocytic Astrocytomas {#Sec11}
------------------------------------------------------------------------------

Profiles from pilocytic astrocytomas were compared with combined adult brain controls, and also with normal adult cerebellum, since this subset of tumors were all located in the cerebellum (Additional file [3](#MOESM3){ref-type="media"}: Table S3). Up- and down-regulated microRNAs compared to normal adult cerebellum are shown in Table [3](#Tab3){ref-type="table"}. Amongst the top up-regulated microRNAs was a cluster located on Xq26.3, consisting of miR-542-5p, miR-542-3p, miR-503, mir-450a and miR-450b-5p (Fig. [2](#Fig2){ref-type="fig"}). The results were not gender-biased. Other top up-regulated microRNAs included miR-224, miR-146a, miR-34a and the miR-106a \~ miR-363 cluster (Table [3](#Tab3){ref-type="table"}).Table 3The top deregulated microRNAs in pilocytic astrocytoma compared to normal adult cerebellumTargetIDp (Corr)FCLog FCa.hsa-miR-2240.0063210.093.33hsa-miR-542-5p0.005589.693.28hsa-miR-542-3p0.023667.512.91hsa-miR-450b-5p0.002856.892.78hsa-miR-5030.001206.802.76hsa-miR-450a0.012116.672.74hsa-miR-886-5p0.005516.172.62hsa-miR-767-5p0.000024.942.31HS_290.018114.412.14hsa-miR-7080.026453.921.97hsa-miR-146a0.010763.841.94hsa-miR-34a0.002683.131.65solexa-539-20560.043793.031.60hsa-miR-335\*0.004862.811.49hsa-miR-18b0.045292.791.48hsa-miR-452\*0.000002.581.37hsa-miR-18a0.004412.561.36hsa-miR-199a\*:9.10.036222.561.36hsa-miR-574-5p0.000002.391.26hsa-miR-296-3p0.029072.361.24hsa-miR-1550.013722.331.22hsa-miR-24-2\*0.000002.331.22hsa-miR-106a0.001492.321.21hsa-miR-21\*0.000732.221.15HS_262.10.018142.161.11hsa-miR-3630.010212.071.05hsa-miR-371-3p0.000022.031.02b.hsa-miR-129-3p0.00062−44.25−5.47hsa-miR-129\*0.00000−27.08−4.76hsa-miR-1224-5p0.00515−16.54−4.05hsa-miR-124a:9.10.00357−15.84−3.99hsa-miR-3260.01508−12.16−3.60hsa-miR-1240.00073−9.66−3.27hsa-miR-2040.00140−9.65−3.27hsa-miR-12960.00000−6.94−2.80hsa-miR-885-5p0.00006−6.76−2.76hsa-miR-128a:9.10.00149−5.78−2.53hsa-miR-2180.00504−5.72−2.52hsa-miR-133b0.00000−5.57−2.48hsa-miR-8740.00013−5.52−2.46hsa-miR-769-3p0.02429−4.96−2.31hsa-miR-485-3p0.01589−4.70−2.23hsa-miR-128b:9.10.00049−4.68−2.23HS_182.10.00140−4.45−2.15hsa-miR-1070.00002−4.38−2.13hsa-miR-3830.00175−4.36−2.12hsa-miR-6560.00825−4.35−2.12hsa-miR-124\*0.03622−4.14−2.05hsa-miR-5840.00130−3.61−1.85hsa-miR-70.00108−3.40−1.77hsa-miR-548k0.01014−3.39−1.76hsa-miR-12370.00149−3.21−1.68hsa-miR-299-5p0.01076−3.20−1.68hsa-miR-11790.01508−2.92−1.55hsa-miR-487b0.03622−2.75−1.46HS_2310.00367−2.73−1.45hsa-miR-3290.00101−2.47−1.30hsa-miR-154\*0.00566−2.47−1.30hsa-miR-8890.01811−2.15−1.11hsa-miR-135a0.02645−2.06−1.04(a) Up-regulated microRNAs and (b) down-regulated microRNAs. Differential expression was defined as fold change (FC) \> 2 with FDR corrected (Benjamini Hochberg) *p-*values \<0.05Fig. 2Expression of a cluster of microRNAs on Xq26.3 in pilocytic astrocytomas. (**a**) Map of microRNA genes showing up-regulated microRNAs transcribed in the same direction. (**b**) Illumina MicroRNA Expression array (MI-v2) data showing up-regulation of miR-503, miR-542-3p, miR-542-5p, miR-450a and miR-450b-5p in pilocytic astrocytoma compared to normal brain controls. The Illumina probe miR-450a contains the seed sequence present in both miR-450a-1 and miR-450a-2

All the pilocytic astrocytomas used in the test cohort contain the *KIAA1549-BRAF* fusion that activates the ERK/MAPK pathway. Analysis of up-regulated microRNAs using TargetScan revealed several predicted targets to be regulators of the MAPK pathway. These included miR-155, which targets *KRAS,* miR-34a, which targets *MAP2K1* (*MEK1*), and miR-503, which targets *MAPK1* (*ERK1*) (Fig. [3](#Fig3){ref-type="fig"}). Other up-regulated microRNAs, including MiR-450b, miR-542-3p and miR-155, are all predicted to target *ETS1, MYC* and *FOS*, which are regulated by MAPK pathway components. In addition, the up-regulated microRNAs, miR-155, miR-199a, miR-21 and miR-146a (Fig. [4a](#Fig4){ref-type="fig"}), target genes within the NF-κB network (Figs. [3](#Fig3){ref-type="fig"}). Analysis of brain-specific microRNAs \[[@CR49]\] showed no significant differences in expression in pilocytic astrocytomas, apart from down-regulation of miR-218. However, the majority of pilocytic astrocytomas showed low expression of neuronal-specific microRNAs, miR-129, miR-124 and miR-128 \[[@CR50], [@CR51]\] (Additional file [3](#MOESM3){ref-type="media"}: Table S3).Fig. 3Model showing the interplay of microRNAs in senescence, proliferation and inflammation. MicroRNAs provide negative feedback of the RB pathway, the MAPK pathway and the NF-κΒ network. MiR-34a and miR-503 are predicted to target *CCND1* and *CDK4* to limit cell proliferation via the RB pathway. MiR-155 is predicted to target *KRAS*, miR-34a is predicted to target *MEK1*, whilst down stream targets of the MAPK pathway include *SPRED1* (a predicted target of miR-503), *SPRY1, SPRY2* and *SPRY4* (predicted targets of miR-450b-5p) and *FOS* and *ETS1* (predicted targets of miR-155). MicroRNAs that act as effectors and regulators of NF-κB include miR-146a, miR-155, miR-199a and miR-21. MiR-146a, miR-224 and miR-155 are predicted to target senescenceassociated genes and thus to regulate levels of inflammationFig. 4Expression of microRNAs and genes involved in senescence in pilocytic astrocytomas. (**a**) Illumina MicroRNA Expression array (MI-v2) data showing miR-146a and miR-155 are up-regulated in the majority of pilocytic astrocytomas and (**b**) Illumina HumanHT-12_v3 expression array data showing a higher level of expression for *CDKN2A, IGFBP7* and *TIMP1* in pilocytic astrocytomas compared to normal brain controls

Oncogene-induced senescence is associated with activation of an inflammatory transcriptome \[[@CR31]\], and since senescence markers have been identified in pilocytic astrocytomas, we examined expression levels of microRNAs and genes known to be associated with senescence. MiR-146a was amongst the top up-regulated microRNAs in pilocytic astrocytomas, and is known to modulate senescence-associated inflammatory mediators (Fig. [4a](#Fig4){ref-type="fig"}) \[[@CR4]\]. Furthermore, *CDKN1A (p21)* and *CDKN2A (p16)* were found to be up-regulated, together with the major transcriptional inducers of senescence-associated secretory phenotype (SASP), *IGFBP7* and *TIMP1* (Fig. [4b](#Fig4){ref-type="fig"})*,* as well as *CEBPB, TIMP2, TIMP3, AXL* and other insulin-like growth factor (IGF)-binding proteins that stimulate inflammation, including *IGFBP2, IGFBP3, IGFBP4* and *IGFBP5* (Additional file [4](#MOESM4){ref-type="media"}: Table S4).

Ingenuity Pathway Analysis was used to compare gene expression data between pilocytic astrocytomas and normal adult cerebellum. The top canonical pathways showing significant up-regulation included *Antigen Presentation Pathway, Graft-*versus*-Host Disease Signaling, Type I Diabetes Mellitus Signaling, Hepatic Fibrosis/Hepatic Stellate Cell Activation* and *Dendritic Cell Maturation.* Analysis of the predicted activation state of up-stream transcription factors showed 70 factors predicted as 'activated' and 28 predicted as 'inhibited' (*p \< 0.05,* activation z-score \> 2.0) (Additional file [6](#MOESM6){ref-type="media"}: Table S6a, b). Predicted 'activated' transcription factors included *NF-kB* complex, *TP53*, *IRF7, CEBPB, JUN, RELA* and *CEBPA*, whilst predicted 'inhibited' transcription factors included *TRIM24, MYC, MYCN,* estrogen receptor and *RB*.

Using TaqMan assays and Real Time qRT-PCR, we confirmed the differential expression of a set of microRNAs and genes in a selection of the *test* tumor cohort, as well as 13 tumors from the *validation* tumor cohort (Additional file [7](#MOESM7){ref-type="media"}: Figure S1 and Additional file [8](#MOESM8){ref-type="media"}: Figure S2). We confirmed up-regulation of miR-34a, miR-146a, miR-542-3p, miR-503 and miR-155 and low expression of neuronal microRNAs miR-124\*, miR-129 and miR-129\* (Additional file [7](#MOESM7){ref-type="media"}: Figure S1). Up-regulation of the senescence factors *IGFBP7, CDKN2A (p16), IL6, IL8, CDKN1A (p21)* and down-regulation of *CTCF* was also confirmed (Additional file [8](#MOESM8){ref-type="media"}: Figure S2).

Discussion {#Sec12}
==========

To gain a comprehensive understanding of tumorigenesis, it is critical to integrate findings on factors that regulate the transcriptome, such as microRNAs, with genomic analysis. This is especially pertinent in the case of pediatric CNS tumors, which have fewer mutational events than their adult counterparts \[[@CR48], [@CR54]\]. MicroRNAs are highly regulated and have essential functions in brain development \[[@CR23], [@CR30]\], and certain microRNAs are enriched or specifically expressed in the adult brain \[[@CR49]\]. Here, we profiled microRNA and gene expression in a cohort of pediatric brain tumors, and then focused on the potential role of microRNAs in pilocytic astrocytomas.

The mitogen-activated protein kinase (MAPK) signaling cascade is the main molecular pathway that is deregulated in pilocytic astrocytomas \[[@CR56]\]. *BRAF*-gene fusions and, in rare cases, *BRAF* V600E mutations give rise to constitutively active *BRAF*, which in turn activates the MAPK pathway. Furthermore, *BRAF* activation has been shown to cause oncogene-induced senescence in vitro \[[@CR24], [@CR42]\]. Hence, we obtained gene expression profiles for pilocytic astrocytomas in order to identify any senescent or inflammatory markers that may explain the less aggressive nature of these tumors. Senescence is accompanied by increased secretion of factors involved in senescent signaling. In pilocytic astrocytomas, we observed up-regulation of *IGFBP7* and *CEBPB*, both of which are major transcriptional inducers of SASP-related genes \[[@CR16]\]. In addition, we observed up-regulation of *IL1B,* which has been shown to be a SASP-associated protein \[[@CR10]\]. Our gene expression profiling of pilocytic astrocytomas also revealed up-regulation of many genes involved in immune function. This was supported by pathway analysis, which showed that pilocytic astrocytomas exhibit a strong immune and inflammatory response.

There is accumulating evidence for a role for certain microRNAs in senescence \[[@CR1], [@CR17], [@CR19]\]. The miR-424-miR-503 polycistron, as well as miR-450, miR-542-3p and miR-450b-5p are suggested to play a role in replicative senescence and cellular aging in fibroblasts \[[@CR6]\]. MiR-424 and miR-503 can induce G1 arrest in THP-1 cells \[[@CR14]\] and may limit proliferation in pilocytic astrocytomas. Recently, expression of miR-542-5p, which is repressed in *MYC*-amplified neuroblastomas was shown to be positively correlated with survival \[[@CR46]\]. Interestingly, *CTCF*, a predicted target of miR-542-3p, is down-regulated in pilocytic astrocytoma, and a recent investigation into the higher-order chromatin structure of the *INK4/ARF* locus in senescent cells, has revealed down-regulation of *CTCF* in oncogene-induced senescent cells \[[@CR20]\].

Predicted targets of differentially regulated microRNAs frequently included components of the ERK/MAPK and NF-κB signaling pathways (Fig. [3](#Fig3){ref-type="fig"}). MiR-503 and miR155 are predicted to target components of the ERK/MAPK pathway, as well as miR-34a which can induce cell cycle arrest by targeting Notch ligand delta-like 1, a component of *NOTCH* signaling \[[@CR11]\], and cell cycle regulators *CCND1* and *CDK6* \[[@CR52]\]. The same microRNAs are also predicted to target components of NF-κB signaling. MiR-155 has many target genes including *IKKε,* suggesting a role in the immune response \[[@CR53]\]. In ovarian tumors, miR-199a negatively regulates *IKKβ* expression to reduce *NF-κB* activity \[[@CR8]\]. *NF-κB* is reported to be a direct transcriptional regulator of miR-224 \[[@CR47]\] and we observe up-regulation of the miR-224 in our pilocytic astrocytomas. In addition, miR-224 has been shown to target the tumor suppressor *RKIP* in human breast cancer \[[@CR22]\]. MiR-146a, which is induced by inflammation in the presence of *NF-κB* and *IL1* receptor signaling to modulate senescent mediators, is up-regulated specifically in pilocytic astrocytomas \[[@CR4]\]. In fibroblasts, miR-146a/b down-regulates *IRAK1* to reduce *IL6* and *IL8* secretion in an elegant feedback loop \[[@CR4]\]. The expression of miR-146a is a late manifestation of senescence \[[@CR43]\] and it is possible that the few pilocytic astrocytomas that do not show elevated expression of miR-146a have not reached a "mature" level of the senescent phenotype.

Brain tissues are composed of multiple neuronal, astroglial, microglial and other cell types, so the relative contributions of each brain cell type to the overall microRNA and gene expression profiles remain to be elucidated. MiR-146a and miR-155 are expressed by activated microglia and astroglial cells in culture \[[@CR7], [@CR34], [@CR44]\]. Therefore, it is possible that some of our up-regulated microRNAs could also potentially represent the proliferating microglia that are reported to be present in pilocytic astrocytomas \[[@CR28]\]. A recent study has demonstrated that increased activation of RAS/ERK signaling in neocortical progenitors produced a *NEUROG2-ASCL1* switch, which promotes glial fate \[[@CR55]\]. This developmental neurogenic to gliogenic switch in transcription factor expression is supported in studies of RAS-driven glioma formation from neural stem cells \[[@CR25], [@CR40]\]. In a recently developed mouse model of gliomagenesis, high RAS/ERK levels were found to modify *Ascl1* activity giving rise to glial tumors \[[@CR33]\], and we observe clear up-regulation of *ASCL1* in the pilocytic astrocytomas (Additional file [4](#MOESM4){ref-type="media"}: Table S4). These authors demonstrated that whilst RAS/ERK signaling is critical for neurodevelopment, *ERK* is the key effector as it phosphorylates the ASCL1 protein resulting in its gliogenic effect. Hence, enhanced RAS/ERK signaling in the pilocytic astrocytomas by activated BRAF may have triggered a gliogenic switch, and this is reflected in the expression of microRNAs that are usually observed in astroglial cells.

Conclusions {#Sec13}
===========

In summary, we show that pilocytic astrocytomas differentially express microRNAs that target genes that encode regulators of the MAPK and NF-κB pathways, as well as genes that are markers of inflammation. These microRNAs and the post-translational regulation of their gene targets may therefore play a role in the unique phenotype of pilocytic astrocytomas.
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Additional file 1: Table S1.Normalized microRNA expression data. (XLSX 841 kb)Additional file 2: Table S2.Normalized gene expression data. (XLSX 37339 kb)Additional file 3: Table S3.Differentially expressed microRNAs in pediatric brain tumors (tumor groups with \> 3 samples). (XLSX 75 kb)Additional file 4: Table S4.Differentially expressed genes in pediatric brain tumors (tumor groups with \> 3 samples). (XLSX 852 kb)Additional file 5: Table S5.(a) List of primer pairs selected for Illumina microRNA expression array (MI-v2) validation. (b) List of primer pairs used to identify *KIAA1549-BRAF* fusion and the *BRAF V600E* mutation. (PDF 58 kb)Additional file 6: Table S6.Ingenuity Pathway Analysis of differentially expressed genes in pilocytic astrocytomas compared to normal adult cerebellum, showing transcription factors with a predicted activation state as (a) 'activated' and (b) 'inhibited'. (PDF 68 kb)Additional file 7: Figure S1.RT-qPCR confirms (a) up-regulation of miR-34a, miR-146a, miR-542-3p and miR-503 in pilocytic astrocytomas. (b) low expression of miR-124\*, miR-129 and miR-129\* in pilocytic astrocytomas. Relative expression shown as Log~2~ fold change compared to normal adult cerebellum and frontal lobe (normalized to miR-423-3p). Data represent two technical replicates ± SD. (ZIP 516 kb)Additional file 8: Figure S2.RT-qPCR confirms (a) up-regulation of *CDKN1A* and *IGFBP7*, (b) up-regulation of *CDKN2A, IL6* and *IL8* and down-regulation of *CTCF* in pilocytic astrocytomas. Relative expression shown as Log~2~ fold change compared to normal adult cerebellum and frontal lobe (normalized to *TBP*). Data represent two technical replicates ± SD. (ZIP 275 kb)
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